Semax Research Peptide

Peptora Compound Research Library

Semax Research Peptide Overview

Semax Research Peptide literature examines the synthetic heptapeptide Met-Glu-His-Phe-Pro-Gly-Pro, also written MEHFPGP. Research has investigated its ACTH-related structure, neurotrophin signalling, BDNF and TrkB expression, gene regulation and experimental models of cerebral ischemia.

Research Library Commonly Studied Peptides Testing & COAs Research Peptides

Compound overview

Semax Research Peptide: What Is Semax?

Semax is a synthetic seven-amino-acid peptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro.

The peptide is commonly described as ACTH(4–7)-Pro-Gly-Pro, reflecting its structural relationship to an N-terminal fragment of adrenocorticotropic hormone combined with the C-terminal PGP tripeptide.

Semax was designed as a modified ACTH-related peptide while lacking the complete structure of the native ACTH hormone. Its scientific literature has subsequently expanded into neurotrophin signalling, gene-expression research and experimental models involving neural tissue.

Semax Sequence

Full sequence: Met-Glu-His-Phe-Pro-Gly-Pro

One-letter sequence: MEHFPGP

Length: seven amino-acid residues

The first four residues correspond to ACTH(4–7), while the final three residues form the Pro-Gly-Pro sequence.

Peptide structure

Semax Research Peptide and Its ACTH-Related Structure

Adrenocorticotropic hormone is a substantially larger peptide. Semax contains only a short sequence related to the N-terminal region of ACTH and therefore should not be described as though it were full-length ACTH.

4–7

ACTH-Related Region

Met-Glu-His-Phe corresponds to the ACTH(4–7) sequence incorporated into Semax.

PGP

Pro-Gly-Pro

The C-terminal Pro-Gly-Pro tripeptide distinguishes Semax from the unmodified ACTH(4–7) fragment.

Heptapeptide

The complete Semax molecule contains seven amino-acid residues.

Structural distinction: Semax is ACTH-related, but it is not full-length ACTH. Findings involving ACTH itself should not automatically be attributed to Semax.

Neurotrophin research

Semax Research Peptide and Neurotrophin Signalling

Neurotrophin regulation is one of the most frequently investigated molecular themes in the Semax literature.

Experimental studies have examined Semax in relation to brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), neurotrophin receptors and associated signalling pathways.

In rat-brain experiments, Semax produced region- and time-dependent changes in Bdnf and Ngf gene expression. Other work reported changes involving BDNF protein and TrkB signalling in rat hippocampal and basal-forebrain models.

BDNF Research

Animal and cell studies have investigated Semax-associated changes in BDNF gene expression and protein levels.

NGF Research

Experimental work has also reported changes in nerve growth factor gene expression under defined laboratory conditions.

TrkB Research

TrkB, an important receptor for BDNF, has been examined in Semax-associated signalling studies.

Regional Differences

Reported neurotrophin responses can differ according to brain region, experimental model and sampling time.

BDNF signalling

Semax and BDNF/TrkB Research

BDNF and its receptor TrkB play important roles in neuronal signalling and synaptic biology, making this pathway a major focus of Semax research.

A rat hippocampal study reported changes in BDNF protein, Bdnf transcription and TrkB-related measures after experimental Semax exposure.

Separate research in rat basal forebrain reported specific Semax binding together with changes in BDNF protein levels.

What BDNF Findings Mean

Changes in BDNF or TrkB under controlled experimental conditions provide evidence about molecular signalling.

They do not independently establish improved cognition, treatment of neurological disease or another specific clinical outcome in humans.

Gene expression

Semax Research Peptide and Gene-Expression Studies

Beyond individual neurotrophins, Semax has been investigated using broader gene-expression and transcriptomic methods.

Studies in rat models have reported changes across genes associated with neurotrophin signalling, immune responses, neurotransmission, cellular stress and other molecular pathways.

More recent RNA-sequencing work has continued to identify changes in brain transcriptomic activity after exposure to ACTH-related synthetic peptides including Semax.

Transcriptomic Evidence Is Mechanistic Evidence

RNA sequencing and gene-expression studies can identify molecular pathways that respond under defined experimental conditions.

A change in gene expression does not by itself demonstrate clinical effectiveness, long-term safety or a specific therapeutic outcome.

Experimental ischemia

Semax Research Peptide in Cerebral-Ischemia Models

A substantial portion of the mechanistic Semax literature uses experimental cerebral-ischemia models in rodents.

Researchers have studied Semax following middle cerebral artery occlusion and other experimental ischemic procedures, examining neurotrophin transcription, inflammatory mediators, protein expression and other molecular responses.

One study found that both Semax and PGP altered transcription of neurotrophins and their receptors in rat cortex after permanent middle cerebral artery occlusion. Other research has investigated inflammatory-gene expression and protein-level responses following ischemia-reperfusion.

Evidence context: experimentally induced cerebral ischemia in rodents is a laboratory model. Results from these models should not be presented as proof of a particular clinical effect in humans.

Immune signalling

Semax and Neuroimmune Research

Transcriptomic research has also connected Semax with changes in immune-response and inflammatory-signalling pathways in experimental brain models.

Studies using rat cerebral-ischemia models have reported altered expression of genes associated with cytokine signalling, immune responses and inflammatory processes.

Later protein-expression studies examined markers involved in inflammation, cellular stress, cell-death pathways and recovery-related signalling.

Inflammatory Genes

RNA-based experiments have identified Semax-associated changes in inflammatory and immune-response transcripts.

Protein Signalling

Experimental work has examined proteins including MMP-9, c-Fos, JNK and CREB in ischemia-reperfusion models.

PGP research

The Pro-Gly-Pro Region of Semax

The C-terminal PGP sequence is an important part of Semax research because PGP can also be studied independently.

Comparative experiments involving Semax and PGP have found both overlapping and distinct gene-expression responses. This suggests that the C-terminal tripeptide may contribute to some experimental effects while the complete Semax molecule retains its own activity profile.

Biodegradation research has also identified PGP among products formed during Semax breakdown in experimental systems.

Semax

MEHFPGP contains both the ACTH(4–7)-related sequence and the C-terminal PGP region.

PGP

Pro-Gly-Pro is a separate tripeptide that has been investigated independently and as a Semax biodegradation product.

Biodegradation

Semax Research Peptide and Peptide Metabolism

Peptide degradation can produce shorter fragments with biological properties that differ from those of the original molecule.

Experimental biodegradation research involving Semax identified the pentapeptide HFPGP and the tripeptide PGP among major products formed in the presence of nerve cells.

Why this matters: research involving the parent Semax molecule should be distinguished from research involving PGP, HFPGP or other fragments produced during peptide degradation.

This principle also connects with the broader considerations discussed in Peptora's Understanding Peptide Stability guide.

Evidence quality

Understanding the Semax Research Evidence

Semax has been investigated using several research approaches, but each evidence type has different limitations.

Evidence Type	Research Focus	Important Limitation
Cell-culture research	Neurotrophin expression, cellular responses and peptide degradation	Cellular findings cannot automatically be generalized to a living organism
Normal-animal studies	BDNF, NGF, TrkB and region-specific gene expression	Animal molecular responses do not establish human outcomes
Ischemia models	Neurotrophins, inflammatory signalling, transcriptomics and protein expression	Experimental rodent ischemia is not equivalent to human disease
Mechanistic studies	Binding, gene regulation, peptide fragments and molecular pathways	Mechanistic evidence alone does not establish clinical efficacy or safety

Research interpretation

What Semax Research Does and Does Not Establish

The published literature supports scientific investigation of Semax across neurotrophin biology, gene expression and experimental neural models.

However, the existence of mechanistic or animal evidence should not be used to imply that a laboratory research material has established effects on memory, cognition, neurological disease or human performance.

✓ BDNF changes are molecular findings.

✓ Rat findings are not automatically human findings.

✓ Ischemia models are experimental systems.

✓ Gene expression does not equal clinical efficacy.

✓ Semax and PGP should be distinguished.

✓ Published research does not verify a supplied batch.

Analytical documentation

Semax Research Peptide: Purity, Identity and Batch Testing

Scientific literature about Semax does not establish the analytical characteristics of an individual laboratory research batch.

Researchers evaluating supplied material should separately review the analytical documentation associated with the applicable batch.

✓ Confirm the stated material identity.

✓ Match documentation to the applicable batch.

✓ Review purity where reported.

✓ Review identity testing where reported.

✓ Review measured content where reported.

✓ Identify the analytical methods used.

✓ Review additional testing only where documented.

✓ Do not transfer one batch's results to another.

For the broader analytical framework, read Peptide Purity & Certificates of Analysis (COAs) Explained and review Peptora's Testing & COAs.

Research network

Continue Exploring Semax and Related Research

This overview connects Semax with Peptora's larger educational network covering research peptides, stability, analytical documentation and compound-specific research.

Related Peptide Research Resources

Continue into foundational research education and other compound overviews.

Commonly Studied Research Peptides in Canada → What Are Research Peptides? → Understanding Peptide Stability → Peptide Purity & COAs Explained → Research Peptides in Canada → MOTS-C Research Peptide Overview → SS-31 Research Peptide Overview → Complete Research Library →

Semax FAQ

Semax Research Peptide: Frequently Asked Questions

Common research questions about Semax, MEHFPGP, ACTH-related structure, PGP and experimental neurotrophin research.

What is the Semax research peptide?

Semax is a synthetic seven-amino-acid peptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro, commonly written MEHFPGP. Experimental research has examined neurotrophin signalling, gene expression and neural research models.

What is the amino-acid sequence of Semax?

The Semax sequence is Met-Glu-His-Phe-Pro-Gly-Pro, or MEHFPGP.

Is Semax the same as ACTH?

No. Semax contains a short sequence related to ACTH(4–7) followed by Pro-Gly-Pro. It is not full-length adrenocorticotropic hormone.

Why is BDNF studied in Semax research?

Experimental cell and animal studies have reported Semax-associated changes in BDNF gene expression, BDNF protein and related TrkB signalling, making neurotrophin biology an important research area.

What is PGP in Semax?

PGP stands for Pro-Gly-Pro, the three-amino-acid sequence at the C-terminal end of Semax. PGP has also been investigated separately in experimental research.

Why is Semax studied in cerebral-ischemia models?

Researchers have used rodent cerebral-ischemia models to investigate Semax-associated changes in neurotrophins, inflammatory signalling, gene expression and protein pathways under defined experimental conditions.

Do animal studies establish human effects of Semax?

No. Animal and cellular studies provide experimental evidence about mechanisms and biological responses but should not be interpreted as proof of specific human clinical effects.

Does published Semax research verify a specific research batch?

No. Published scientific studies describe research involving defined materials. A specific laboratory batch must be evaluated using the analytical documentation associated with that batch.

Research use only

Semax Research Peptide for Controlled Laboratory Research

This overview provides educational information about Semax and areas investigated in published scientific literature. Findings from cultured cells, animal experiments, cerebral-ischemia models and gene-expression research should not be interpreted as established human clinical effects.

Peptora Peptide Labs research products are intended solely for controlled non-clinical laboratory research. They are not intended for human or veterinary consumption, compounding or clinical use. Nothing on this page provides medical advice, dosing or administration guidance, or representations concerning diagnosis, treatment, cure or prevention of disease.